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Abstract
Background: Basic studies of oncogenesis have demonstrated that either the elevated production
of particular oncogene proteins or the occurrence of qualitative abnormalities in oncogenes can
contribute to neoplastic cellular transformation. The purpose of our study was to identify an unique
gene that shows cancer-associated expression, and characterizes its function related to human
carcinogenesis.
Methods: We used the differential display (DD) RT-PCR method using normal cervical, cervical
cancer, metastatic cervical tissues, and cervical cancer cell lines to identify genes overexpressed in
cervical cancers and identified gremlin 1 which was overexpressed in cervical cancers. We
determined expression levels of gremlin 1 using Northern blot analysis and immunohistochemical
study in various types of human normal and cancer tissues. To understand the tumorigenesis
pathway of identified gremlin 1 protein, we performed a yeast two-hybrid screen, GST pull down
assay, and immunoprecipitation to identify gremlin 1 interacting proteins.
Results: DDRT-PCR analysis revealed that gremlin 1 was overexpressed in uterine cervical cancer.
We also identified a human gremlin 1 that was overexpressed in various human tumors including
carcinomas of the lung, ovary, kidney, breast, colon, pancreas, and sarcoma. PIG-2-transfected HEK
293 cells exhibited growth stimulation and increased telomerase activity. Gremlin 1 interacted with
homo sapiens tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta
polypeptide (14-3-3 eta; YWHAH). YWHAH protein binding site for gremlin 1 was located
between residues 61–80 and gremlin 1 binding site for YWHAH was found to be located between
residues 1 to 67.
Conclusion: Gremlin 1 may play an oncogenic role especially in carcinomas of the uterine cervix,
lung, ovary, kidney, breast, colon, pancreas, and sarcoma. Over-expressed gremlin 1 functions by
interaction with YWHAH. Therefore, Gremlin 1 and its binding protein YWHAH could be good
targets for developing diagnostic and therapeutic strategies against human cancers.
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Background
The identification of molecular alterations in cancerous
and pre-cancerous cells has provided insight into the role
of oncogenes and tumor suppressor genes in tumor initi-
ation and progression [1]. Oncogenes are derived from
highly conserved proto-oncogenes that are altered by
chromosomal point mutations, gene amplifications, or
gene rearrangements [2]. Structural alteration of proto-
oncogenes leads to a quantitative or qualitative change in
the expression of the corresponding protein product. The
signal transduction pathways subverted by oncoproteins
govern fundamental cell functions, including prolifera-
tion, cell cycle regulation, and apoptosis [3].
Although genetic characterization of tumor tissues dem-
onstrates that mutation of the p53 gene is the most com-
mon genetic alteration in human cancers, the mutation
ratio of the p53 gene in uterine cervical cancer is relatively
low [4,5]. It suggests that there are other oncogenes
involved in cervical carcinogenesis. We applied the DDRT-
PCR method to discover genes involved in tumorigenesis
of human cervical tissue, and identified the new human
cervical cancer-related gene, proliferation-inducing gene 2
(PIG-2) (GenBank accession number AY232290), which
exhibits close similarity to gremlin 1 cDNA (GenBank
accession number NM_013372) in the database.
The Drm (also known as gremlin) and its independently
isolated Xenopus homolog, gremlin, a 184-aa protein ini-
tially identified through differential screening as a tran-
scriptional down-regulated gene in v-mos-transformed rat
embryonic fibroblasts [6], belongs to the Dan family of
secreted glycosylated proteins [7,8], which contains a
highly conserved cysteine knot domain shared by the
TGF-β superfamily, PDGF, nerve growth factor, and other
secreted proteins [9]. Drm and Dan regulate early devel-
opment [10-13], tumorigenesis [6,14,15], and renal
pathophysiology [16].
Gremlin gene encodes a member of the bone morpho-
genic protein (BMP) antagonist family. Like BMPs, BMP
antagonists contain cystine knots and typically form
homo- and heterodimers. The cerberus and dan subfamily
of BMP antagonists, to which this gene belongs, is charac-
terized by a C-terminal cystine knot with an eight-mem-
bered ring. The antagonistic effect of the secreted
glycosylated protein encoded by this gene is likely due to
its direct binding to BMP proteins. As an antagonist of
BMP, this gene may play a role in regulating organogene-
sis, body patterning, and tissue differentiation. In mouse,
this protein has been shown to relay the sonic hedgehog
signal from the polarizing region to the apical ectodermal
ridge during limb bud outgrowth [17].
The action of Drm and Dan on development and possibly
diabetic nephropathy is mediated by heterodimerizing
with certain BMPs [9], in particular BMP2, 4, and 7
[7,8,16,18] to subsequently block the ability of BMPs to
bind their receptors [7,18,19]. Chen et al. have previously
shown that the capacity of Drm to suppress transforma-
tion and tumorigenesis [6,14,15] is mediated by a mech-
anism that is independent of BMPs and involves both up-
regulation of p21Cip1  and down-regulation of p42/44
MAPK [14], suggesting additional target(s) for Drm and
other Dan family members.
To identify additional target proteins for PIG-2 which
exhibits close similarity to gremlin 1, we used a yeast two-
hybrid screening approach with a PIG-2-LexA fusion con-
struct as the bait to search for potential PIG2-binding part-
ners. This approach identified homo sapiens tyrosine 3-
monooxygenase/tryptophan 5-monooxygenase activa-
tion protein, eta polypeptide (14-3-3 eta; YWHAH) [20-
28] as one type of the PIG-2-interacting proteins. Thus,
the data demonstrate that Gremlin 1 functionally interacts
with YWHAH protein to act as an oncoprotein for the gen-
esis of human cancers.
Methods
Tissues and cell lines
For Differential display (DD) of mRNA, normal exocervi-
cal tissue specimen was obtained from uterine myoma
patients during hysterectomy and untreated primary cervi-
cal cancer tissues and metastatic lymph node tissues were
obtained during radical hysterectomy. Patient consent
was obtained from each individual and the use of tissue
samples was approved by the ethics committee of our
institution. The cervical caner cell line used in DD was
CasKi and CUMC-6 which was isolated in our laboratory
and maintained as previously described [29]. Mammalian
cell lines described below were all obtained from the
American Type Culture Collection (ATCC; Manassas, VA,
USA): CasKi is a human cervical cancer cell line. NCI-
H441, NCI-H157, and NCI-H2009 are human lung can-
cer cell lines.
DDRT-PCR
Total RNA was extracted from tissues and cells using RNA
extraction kit (RNeasy total RNA kit; Qiagen Inc., Valen-
cia, CA) and 0.2 µg of total RNA was used to generate
cDNA in reverse transcription reaction (RNAimage™ kit,
GenHunter, MA). With the use of the differential display
kit (RNAimage™ kit), we performed PCR using oligo-dT
primers and arbitrary sequences, each 13 bases in length
according to the manufacturer's recommendations [30].
After cDNAs of 3' termini of mRNAs were generated, the
PCR products were separated by electrophoreses on a 6%
denaturing polyacrylamide gel. Bands representing
cDNAs of interest were excised from dried sequencing gel.BMC Cancer 2006, 6:74 http://www.biomedcentral.com/1471-2407/6/74
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The cDNAs were eluted in distilled water by boiling for 15
minutes and then were reamplified without [α-35S]dATP,
and with 20 µM dNTPs instead of 2 µM dNTPs. From the
films, a 282 bp cDNA (referred to as CC282) was identi-
fied that was expressed in primary cervical cancer tissue,
metastatic lymph node and cervical cancer cell lines but
not in normal cervical tissue. CC282 was identified by the
use of 5' arbitrary primer H-AP28 (5' -AAGCTTACGATGC-
3') and 3' H-T11C anchored primer (5' -
AAGCTTTTTTTTTTTC-3') (GenHunter). CC282 was then
subcloned into pGEM-T easy vector with the use of the TA
cloning system and sequenced with the use of the Seque-
nase Version 2.0 DNA Sequencing System (United States
Biochemical Co., Cleveland, OH).
Northern blot analysis
Total RNA was extracted from fresh human tissues and cell
lines using RNeasy total RNA kit (Qiagen). Northern blot
analysis was carried out, in which 20 µg of denatured total
RNA was electrophoresed on a 1.0% formaldehyde agar-
ose gel and transferred to nylon membrane (Roche Diag-
nostics GmbH, Mannheim, Germany). The mRNA
expression of PIG-2 was also assessed in normal human
tissues and a variety of human cancer cell lines with the
use of prepared membranes obtained from Clontech
(Palo Alto, CA) and processed as recommended by the
supplier. Human β-actin cDNA control probe provided by
Clontech was used as a loading control. All blots were
hybridized with the randomly primed [32P]-labeled PIG-2
partial cDNA probe (the CC282 fragment).
Growth curve
To test the effect of PIG-2 gene on HEK 293 cell growth, 1
× 105 wild-type HEK 293 cells, PIG-2 gene transfected
HEK 293 cells, and HEK 293 cells transfected with
pcDNA3.1 alone were cultured for 13 days. In three inde-
pendent experiments, cells in triplicate flasks were
detached and viable cells counted every other day using
trypan blue dye exclusion.
Transformation and morphology
PIG-2-transfected HEK 293 cells were maintained in cul-
ture for 4–5 weeks with the corresponding media replaced
every 3 days and monitored microscopically. HEK 293
nontransformed cells were seeded in parallel. To examine
cell morphologies, clones of HEK 293 cells stably trans-
fected with the PIG-2 gene were grown to approximately
70% of confluency in culture flasks, and photographed by
Olympus (Inha, Japan) phase-contrast microscopy (mag-
nification, × 100).
Immunohistochemistry
For immunohistochemistry, cryosections (5 µm thick) of
human normal and cancer tissues were used. The sections
were deparaffinized with xylene and ethanol. After wash-
ing with tap water, the sections were treated with meth-
anolic H2O2  for 30 minutes. Before incubation with
primary antibody, the sections were permeabilized by
incubation in 0.5% Triton X-100 in phosphate-buffered
saline (PBS) for 15 minutes and then blocked with nor-
mal goat serum for 15 minutes. The sections were incu-
bated with polyclonal anti-Gremlin antibody (IMGENEX,
San Diego, CA) for 2 hours at room temperature. After
three washes with PBS, the sections were sequentially
incubated with biotinylated species-specific secondary
antibodies (Vector Laboratories, Burlington, CA) for 1
hour at room temperature, and then avidin and bioti-
nylated horseradish peroxidase according to the manufac-
turer's recommendations. Aminoethyl carbozole (AEC)
was used as the chromogen. After immunostaining, sec-
tions were counterstained with hematoxylin. Sections
were photographed on an Olympus photomicroscope
(Inha, Japan).
Telomerase activity assay
Telomerase activity was measured with the Telo TAGGG
Telomerase PCR-ELISA kit (Roche, Germany). The kit pro-
vides an immortalized human 293 kidney cell extract as a
positive control and 293 cell extract pretreated with RNase
as a negative control. All the experiments were performed
in triplicate.
Yeast two-hybrid screening and β-galactosidase assay
The MATCHMAKER LexA two-hybrid system was used to
identify proteins from the human fetal brain MATCH-
MAKER cDNA library that could bind a PIG-2 fusion pro-
tein (Clontech, Palo Alto, CA). All experiments were
performed in the yeast strain EGY48 transformed with
p8op-lacZ, which expresses lacZ and leu genes as reporters
(Clontech). We inserted a PIG-2 cDNA fragment into a
yeast two-hybrid vector (pLexA) (Clontech) containing
the LexA DNA-binding domain. Yeast cells expressing the
LexA-PIG-2 were transformed with a human fetal brain
cDNA library (Invitrogen) that expresses B42AD fusion
proteins. After library transformation, cells are plated on
minimal synthetic dropout non-induction medium
(Sigma) that selects for both the bait (PIG-2) and the AD/
library plasmids to improve the chances of detecting AD
fusion proteins. To confirm the interaction between PIG-
2 and binding protein YWHAH, plasmids expressing PIG-
2 and YWHAH were co-transformed into yeast cells. β-
galactosidase filter lift assays were performed by replica-
plating the co-transformants expressing PIG-2 and
YWHAH on Trp-, Leu-, His- selection plates. We used a
yeast mating assay to eliminate false positive interactions.
GST-tagged YWHAH protein expression and pull down 
experiments
GST-tagged proteins were expressed and extracts were pre-
pared as recommended by the manufacturer (AmershamBMC Cancer 2006, 6:74 http://www.biomedcentral.com/1471-2407/6/74
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Identification and expression level of PIG-2 Figure 1
Identification and expression level of PIG-2. A) Comparison gene expression profiles by DDRT-PCR from total RNA iso-
lated from normal cervical tissue, primary cervical cancer, cervical cancer tissue metastatic to lymph node and from CasKi and 
CUMC-6 cervical cancer cell lines. Differential display was carried out 5' arbitrary primer H-AP28 (5' -AAGCTTACGATGC-
3') and 3' H-T11C (5' -AAGCTTTTTTTTTTTC-3'). The PCR products were resolved by electrophoresis. CC282 is the name 
of the partial PIG-2 gene product. The arrow identifies the location relative to other PCR products. (B) Total RNAs were iso-
lated from normal cervical tissue, primary cervical cancer, cervical cancer tissue metastatic to lymph node and from CasKi and-
CUMC-6 cervical cancer cell lines. Blot was hybridized with the randomly primed [32P]-labeled PIG-2 partial cDNA probe (the 
CC282 fragment). Human β-actin cDNA was used as a control probe (lower panel).BMC Cancer 2006, 6:74 http://www.biomedcentral.com/1471-2407/6/74
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Pharmacia Biotech). E.coli (strain BL21) extracts contain-
ing GST alone, GST-YWHAH and PIG-2 deletion mutants
or GST-PIG-2 and YWHAH deletion mutants were incu-
bated with 30 µl of glutathione-sepharose in 500 µl of
lysis buffer (20 mM Tris-HCl [pH 6.8], 50 mM NaCl, 0.1
mM EDTA, 0.1% Triton X-1000, containing 1 mM phenyl-
methylsulfonyl fluoride, 5 mM dithiothreitol, 1 mg/ml
leupeptin, 1 mg/ml aprotinin, and 1.5 mg/ml pepstatin)
for 12 hours at 4°C. Fusion proteins bound to sepharose
beads were quantitated by Commassie blue staining on
SDS-polyacrylamide gels. The fusion protein-bound
beads were washed three times with 500 µl of TEN buffer
(20 mM Tris HCl [pH 7.4], 0.1 mM EDTA, 100 mM NaCl).
For GST pull down experiments, fusion proteins bound to
the beads were incubated with proteins from HEK 293
total cell extracts expressing PIG-2 or YWHAH for 12
hours at 4?. The beads were washed using NETN buffer
(0.5% Nonidet P-40, 0.1 mM EDTA, 20 mM Tris HCl [pH
7.4], 300 mM NaCl) and eluted with 30 ml of SDS sample
buffer (75 mM Tris-HCl [pH 6.8], 0.5% glycerol, 1% SDS,
4% mercaptoethanol, 0.01% bromophenol blue), and
boiled for 3 minutes before separating on an 10% SDS-
polyacrylamide gel. Eluted proteins were subjected to
western blot analysis.
Immunoprecipitation and Western blot
To confirm the interaction between PIG-2 and binding
protein YWHAH, HEK 293 cells were co-transfected with
pFLAG-CMV (Invitrogen, Carlsbad, CA) encoding the
full-length of PIG-2 and pcDNA3.1-Myc-His/YWHAH
(Invitrogen). After 48 hours, the cells were harvested and
lysed with RIPA buffer (20 mM Hepes [pH 7.2], 1% Triton
X-100, 1% sodium deoxycholate, 0.2% SDS, 150 mM
NaCl, 1 mM Na3VO4, 1 mM NaF, 10% glycerol, 10 g/ml
leupeptin, 10 g/ml aprotinin, 1 mM phenymethylsulfonyl
fluoride). The lysates were precleared with preimmune
serum (mouse) and protein A-Sepharose at 4°C for 30
minutes. Protein concentrations were determined using
the BioRad Protein Assay (Bio-Rad, Hercules, CA) with
bovine serum albumin as a standard. Aliquots (1 mg) of
precleared cell lysates were incubated with a 1:500 dilu-
tion of anti-FLAG (Sigma, F3165) or 1:500 dilution of
anti-Myc (Santa Cruz, 9E10) monoclonal antibody
(mAb) and 40 ml of a 1:1 slurry of protein A-Sepharose
beads in PBS for 4 hours at 4°C. The immune complexes
were collected by centrifugation (2,000 × g for 5 minutes
at 4°C), washed five times with a buffer (20 mM Tris, pH
7.5, 1 mM EDTA, 1 mM EGTA, 150 mM NaCl, 2 mM
Na3VO4, 10% glycerol and 1 % Nonidet P-40), and sub-
jected to SDS-PAGE (10%~12%). Separated proteins were
transferred to nitrocellulose membranes (Schleicher and
schuell), blocked with 5% nonfat dry milk in TBST buffer
(20 mM tris-HCl [pH 7.6], 150 mM NaCl, and 0.5%
Tween20) for 2 hours at room temperature. Blot washed
two times in TBST buffer, primary antibodies incubated
with a 1:1000 dilution of anti-Myc or 1:4000 dilution of
anti-FLAG antibodies in TBST for overnight at 4°C. Blot
was washed three times in TBST, and then incubated with
goat anti-mouse secondary antibody conjugated to horse-
radish peroxidase (Sigma), and washed four times in
TBST. Bound protein visualized using the Super signal
west pico chemiluminescent substrate (PIERCE) followed
by autoradiography for 15 seconds~60 minutes.
Results
Identification of the PIG-2 gene and different expressions 
of PIG-2 in human cervical tissues
To identify oncogenes that may be responsible for the for-
mation of cervical and other cancers, we used differential
display RT-PCR and identified the 200 bp partial cDNA
fragment CC282. As shown in Figure 1A, among the mul-
tiple bands, CC282 was strongly expressed in cervical can-
cer tissue, metastatic lymph node tissue, and CasKi and
CUMC-6 cervical cancer cells, but not normal cervical tis-
sue. Using the partial cDNA CC282 as a probe, we
screened normal human lung, normal uterine cervical tis-
sue, and cervical cancer cDNA library to identify the full-
length cDNA. One clone with size of 4151 bp was isolated
from the human lung cDNA library. This clone, named
PIG-2 for human proliferation-inducing gene 2 (GenBank
accession number AY 232290), encoded a polypeptide of
184 amino acids with a predicted relative molecular mass
of 21 kDa. PIG-2  exhibited 99% homology with the
recorded human gremlin 1, cysteine knot superfamily,
homolog (Xenopus laevis) (GREM1), mRNA sequence
(GenBank accession number NM_013372). The CC282
partial cDNA identified in the differential display corre-
sponded to nucleotides 3901–4100 of PIG-2. Next, we
performed Northern blot analysis to examine the expres-
sion of PIG-2 in normal cervical tissues, cervical cancer tis-
sues, metastatic lymph node tissues, and cervical cancer
cell lines human tissue using the CC282 partial cDNA
fragment. PIG-2 (~4.5 kb) mRNA was strongly expressed
in cervical cancer tissue, metastatic lymph node tissue,
and cervical cancer cells. I normal cervical tissues, the
expression of PIG-2 was very low (Figure 1B).
Differential expression of PIG-2 in various types of human 
normal and cancer tissues
Northern blot analysis was performed to examine the
expression of PIG-2 in human tissue using the CC282 par-
tial cDNA fragment. A transcript of approximately 4.5 kb
is present in skeletal muscle, colon, and small intestine tis-
sues examined, as well as a weaker band at 3.7 kb in colon
and small intestine (Figure 2A). The levels of mRNA
expression were quantified by comparison with the levels
of expression of β-actin. We also examined the expression
of PIG-2  in several cancer cell lines. PIG-2  mRNA was
overexpressed only in human lung cancer cell line A549.
A dominant transcript of 4.5 kb is present in lung cancerBMC Cancer 2006, 6:74 http://www.biomedcentral.com/1471-2407/6/74
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Expression of PIG-2 in human tissues by Northern analyses and immunohistochemical studies Figure 2
Expression of PIG-2 in human tissues by Northern analyses and immunohistochemical studies. Northern blotting 
analyses were performed to determine the expression of PIG-2 in different human tissues. Normal 12 lane multiple tissue 
northern blot (A) or human cancer cell line multiple northern-blot purchased from Clontech (B) was probed with a radioac-
tively labeled CC282 partial cDNA (upper panel) or human β-actin cDNA control probe provided by Clontech (lower panel). 
(C) Total RNAs were isolated from normal lung tissue, primary lung cancer and from NCI-H441, NCI-H157 and NCI-H2009 
lung cancer cell lines. Blot was hybridized with the randomly primed [32P]-labeled PIG-2 partial cDNA probe (the CC282 frag-
ment). Human β-actin cDNA was used as a control probe (lower panel). (D) Comparison of PIG-2 mRNA expression in human 
tumor tissues and their corresponding normal counterparts (upper panel). Total RNAs were extracted from fresh human nor-
mal and cancer tissues. The same blot was probed with β-actin as a loading control (lower panel). (E-I) Immunohistochemical 
staining for PIG-2 expression of human normal muscle (E), leiomyosarcoma (F), normal colon tissue (G), colon cancer (H), 
and pancrease cancer tissue (I), Original magnification, × 100.BMC Cancer 2006, 6:74 http://www.biomedcentral.com/1471-2407/6/74
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Morphology, growth curve and telomerase activity in PIG-2-transfected HEK 293 cells Figure 3
Morphology, growth curve and telomerase activity in PIG-2-transfected HEK 293 cells. (A) Phase-contrast features 
of wild-type HEK 293 cells (left panel), cells transfected vector alone (middle panel), and cells transfected with PIG-2 gene (left 
panel). Magnifications, × 100.(B) Growth stimulatory effect of PIG-2 in HEK 293 cells. PIG-2 induces growth stimulation in 293 
cells. Viability of 293 cells after transfection with PIG-2 or pcDNA3.1 vector alone, respectively. The data are the number of 
viable cells grown for 13 days in culture and represent the mean ± S.D. of triplicate determinations. (C) Determination of tel-
omerase activity. Human telomerase-positive embryonic kidney 293 cells, 293 cell extracts treated with RNase (+ RNase), 
wild-type 293 cells, cells transfected with vector alone and cells transfected with PIG-2 were analyzed by Telomerase PCR 
ELISA. Assays were performed according to the kit protocol with amounts of extracts equivalent to 1 × 103 cells. The telomer-
ase activity in 293 cells, which served as a positive control, was abolished by pretreatment with RNase. Results are the average 
mean absorbance values from three separate experiments (means and 95% confidence intervals).BMC Cancer 2006, 6:74 http://www.biomedcentral.com/1471-2407/6/74
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cells. In addition, a transcript of approximately 3.7 kb was
also present in A549 lung cancer cells (Figure 2B). There
was no expression of PIG-2 in promyelocytic leukemia cell
line HL-60, human cervical cancer cell line HeLa, chronic
myelogenous leukemia cell line K-562, lymphoblastic
leukemia cell line MOLT-4, Burkitt's lymphoma cell line
Raji, colon cancer cell line SW480, and melanoma line
G361. Because PIG-2  was overexpressed only in A549
Protein-interaction of PIG-2 Figure 4
Protein-interaction of PIG-2. (A)PIG-2 binds to YWHAH. Co-immunoprecipitation from transfected HEK 293 cells pro-
ducing PIG-2 and YWHAH proteins was done. Immunoprecipitation was performed with anti-Myc mAb. The protein in the 
pellets was detected with anti-FLAG mAb. (B) YWHAH binds to PIG-2. Co-immunoprecipitation from transfected HEK 293 
cell lines producing YWHAH and PIG-2 proteins was done. Immunoprecipitation was performed with anti-FLAG mAb. The 
protein in the pellets was detected with anti-Myc mAb.BMC Cancer 2006, 6:74 http://www.biomedcentral.com/1471-2407/6/74
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lung cancer cells among 8 cancer cell lines tested, we stud-
ied the expression levels of PIG-2 in normal lung tissues,
fresh primary lung cancer tissues, and lung cancer cell
lines (NCI-H441, NCI-H157 and NCI-H2009). Northern
blot analysis revealed that fresh primary human lung can-
cer tissues and lung cancer cell lines showed increased
expression of PIG-2 levels compared to normal lung tis-
sues (Figure 2C). Northern blot analysis also revealed that
fresh primary human tumor tissues, including carcinomas
of the ovary, kidney and breast, showed increased expres-
sion of PIG-2 when compared with their normal counter-
parts (Figure 2D).
Using anti-gremlin polyclonal antibody, normal or cancer
tissue from muscle, colon and pancreas were subjected to
immunohistochemical experiments. As a result, PIG-2
was over-expressed in all muscle, colon and pancreas can-
cer tissues. The immunoreactivity was observed mainly in
cancer cells with a cytoplasm dominant manner (Figures
2F, 2H and 2I). In corresponding normal muscle and
colon tissues, there were very weak expressions of PIG-2
(Figures 2E and 2G). Although further investigation with
larger number of samples will be needed, these results
indicate that increased expression of the PIG-2 may be
associated with human carcinogenesis.
Morphological changes of HEK 293 cells after transfection 
with PIG-2 gene
Human embryonic kidney (HEK) 293 cells, a differenti-
ated fibroblast cell line, is a spindle shaped fibroblast cell
having a long slender nucleus and a scanty amount of
cytoplasm (Figure 3A; left panel). There were no discerna-
ble differences in cell morphology between wild-type HEK
293 cells and cells transfected with vector alone (Figure
3A; middle panel). But HEK 293 cells expressing PIG-2 are
altered to polygonal cells with an ovoid nucleus and
plump cytoplasm (Figure 3A; right panel).
Growth stimulation of HEK 293 cells by PIG-2
The rate of PIG-2-transfected HEK 293 cell growth was
increased compared to those of cells transfected with vec-
tor alone or wild-type HEK 293 cells. About 150% of PIG-
2-transfected HEK 293 cells remained viable at 13 days
when compared with wild-type HEK 293 cells (Figure 3B).
Telomerase activity in the PIG-2-transfected HEK 293 cells
Alterations in telomere biology both suppress and facili-
tate malignant transformation by regulating genomic sta-
bility and cellular life span [31]. Telomerase is an
enzymatic ribonucleoprotein complex that acts as a
reverse transcriptase in the elongation of telomeres. Tel-
omerase activity is almost absent in somatic cells, but it is
detected in embryonic stem cells and in the vast majority
of tumor cells [32]. To explain the possible oncogenic role
of  PIG-2-transfected cells, we determined telomerase
activity in PIG-2-transfected HEK 293 cells. Wild-type
HEK 293 cells showed detectable telomerase activity (Fig-
ure 3C). PIG-2  gene transfection increased telomerase
activity up to about 2-fold when compared with HEK 293
wild-type cells (Figure 3C).
PIG-2 interacts with YWHAH in vivo
To understand the PIG-2 tumorigenesis pathway, we per-
formed a yeast two-hybrid screen and identified the
YWHAH protein, encoded by the gene homo sapiens tyro-
sine 3-monooxygenase/tryptophan 5-monooxygenase activation
protein, eta polypeptide (GenBank accession number
NM_003405), was interacted with PIG-2. The interaction
of PIG-2 and YWHAH identified by yeast two hybrid
screen was confirmed by glutathione-S-transferase (GST)
pull-down experiments and immunoprecipitation studies
in vitro. The physical interaction between PIG-2 and
YWHAH was examined in vivo by co-immunoprecipita-
tion in HEK 293 cells. The FLAG epitope-tagged PIG-2 was
transiently overexpressed together with the Myc-tagged
YWHAH in HEK 293 cells, and the cell lysates were immu-
noprecipitated with the anti-Myc antibody and detected
by western blotting with anti-FLAG antibody (Figure 4A).
We also performed the immunoprecipitation of reverse
form of co-expression, YWHAH-Myc and PIG-2-FLAG
proteins, in vivo (Figure 4B). As shown in Figure 4A, PIG-
2 could be co-immunoprecipitated with YWHAH, indicat-
ing that YWHAH is likely to be a binding partner. Taken
together, co-immunoprecipitation showed that PIG-2
binds YWHAH protein (Figure 4).
GST full down assays
To investigate the domain of interaction between PIG-2
and YWHAH, we have used four GST fusion constructs,
YWHAH (1–60), YWHAH (1–80), YWHAH (1–100), and
YWHAH (81–247), prepared using YWHAH cDNA as
template DNA, and by PCR amplification. Consistent
with the yeast-two hybrid results, the GST pull-down
assay (Figure 5A) showed that two GST-YWHAH con-
structs, YWHAH (1–80) and YWHAH (1–100) bind PIG-
2, but not GST alone, YWHAH (1–60) and YWHAH (81–
247). To further confirm the direct interaction of PIG-2
and YWHAH in vitro, the GST pull-down assays were per-
formed with the GST-tagged PIG-2 proteins and the
lysates of HEK 293 cells expressing full-length YWHAH
were incubated with the resin-bound GST-PIG-2 proteins,
and the pulled down samples were detected using anti-
Myc antibodies. The GST pull-down assay (Figure 5B)
showed that GST-PIG-2 (1–67), GST-PIG-2 (1–100) and
GST-PIG-2 (1–147), but not GST alone, selectively pulled
down with the full-length YWHAH. The PIG-2 binding
site for YWHAH was found to be located between residues
1 to 67, which is not included in the DAN domain, may
play an important role in the YWHAH-specific interaction
as a novel protein binding domain. Therefore, the bindingBMC Cancer 2006, 6:74 http://www.biomedcentral.com/1471-2407/6/74
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Association of PIG-2 and YWHAH Figure 5
Association of PIG-2 and YWHAH. (A) Mapping of PIG-2 binding domain of YWHAH. Five GST fusion constructs, Full-
YWHAHp1-247, YWHAHp1-100, YWHAHp1–80, YWHAHp1–60 and YWHAHp81–247 were prepared using YWHAH 
cDNA as a template DNA. The GST pull-down assay showed that Three GST-YWHAH constructs, Full-YWHAHp1–247, 
YWHAHp1–100 and YWHAHp1–80 bind YWHAH, but not YWHAHp1–60 and YWHAHp60–247. The YWHAH binding site 
for PIG-2 was delineated to be residues 61–80 (black box). (B) Mapping of YWHAH binding domain of PIG-2. Four GST fusion 
constructs, Full-PIG-2p1-184, PIG-2p1-144, PIG-2p1-100 and PIG-2p1-67 were prepared using PIG-2 cDNA as a template 
DNA. The GST pull-down assay showed all constructs, The PIG-2 binding site for YWHAH was delineated to be residues 1–
67. Gray box is DAN domain. (C) Schematic diagram shows X-ray crystallography of YWHAH protein. PIG-2 protein binding 
site was indicated by arrow.BMC Cancer 2006, 6:74 http://www.biomedcentral.com/1471-2407/6/74
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analysis indicates that the YWHAH binding site for PIG-2
is located between residues 61–80, which constructively
include in the α helix C-α helix D linker, may play an
important role in this intracellular interaction (Figure
5C).
Discussion
To discover genes involved in human cervical carcinogen-
esis, we applied DDRT-PCR and identified the candidate
human cervical cancer-related gene, proliferation-induc-
ing gene 2 (PIG-2) (GenBank accession number
AY232290). PIG-2 exhibited close similarity (99%) to
gremlin 1 cDNA (GenBank accession number
NM_013372) in the database.
Drm/Gremlin and Dan, two homologous secreted antag-
onists of bone morphogenic proteins, have been shown to
regulate early development, tumorigenesis, and renal
pathophysiology [6,10-16]. Topol et al. had previously
shown that most tumor-derived cells fail to express Drm
[33] and that in fibroblasts Drm expression is inhibited
following oncogene-induced transformation [6]. Human
Drm maps to chromosome 15q13-q15, within a region
whose loss is associated with metastatic breast cancer and
other metastatic carcinomas [34]. These properties sug-
gested that Drm might play an inhibitory role in cell trans-
formation or tumorigenesis. They also demonstrated that
overexpression of Drm in the tumor-derived cell lines
Daoy (primitive neuroectodermal) and Saos-2 (osteoblas-
tic) significantly inhibited tumorigenesis and provided
evidence that Drm can function as a novel transformation
suppressor and suggested that this may occur through its
affect on the levels of p21Cip1 and phosphorylated p42/44
MAPK [14,35]. Recent publication also demonstrated that
gremlin mRNA is expressed in non-malignant epithelial
cells and lost in many human cancer cell lines via pro-
moter methylation [36]. Similar finding is also reported
by other group [31].
On the contrary, our experiments showed that PIG-2
which is identical with gremlin 1 was overexpressed in
various human tumors including carcinomas of the cer-
vix, lung, ovary, kidney, breast, colon, pancreas and sar-
coma. However, expression of PIG-2 was generally down-
regulated in diverse human normal tisues. In our experi-
ments, PIG-2-transfected HEK 293 cells exhibited growth
stimulation and increased telomerase activity. Although
further investigation with larger number of samples will
be needed, it suggests PIG-2 may play a fundamental
oncogenic role in multiple body organs.
However, it is unknown how PIG-2 contributes to the cel-
lular and biochemical mechanisms of human tumorigen-
esis. In this study, we identified an oncogene that is
expressed in multiple different human cancers, and inves-
tigated whether the oncogene is responsible for the gene-
sis of human cancer. To understand the PIG-2
tumorigenesis pathway, we performed a yeast two-hybrid
screen and identified the 14-3-3 eta (YWHAH) protein
was interacted with PIG-2 [20-28].
This gene product belongs to the 14-3-3 family of proteins
which mediate signal transduction by binding to phos-
phoserine-containing proteins. This highly conserved pro-
tein family is found in both plants and mammals, and this
protein is 99% identical to the mouse, rat and bovine
orthologs. This gene contains a 7 bp repeat sequence in its
5' UTR, and changes in the number of this repeat has been
associated with early-onset schizophrenia [26].
The 14-3-3 proteins are a family of conserved regulatory
molecules expressed in all eukaryotic cells. A striking fea-
ture of the 14-3-3 proteins is their ability to bind a multi-
tude of functionally diverse signaling proteins, including
kinases, phosphatases, and transmembrane receptors.
This plethora of interacting proteins allows 14-3-3 to play
important roles in a wide range of vital regulatory proc-
esses, such as mitogenic signal transduction, apoptotic
cell death, and cell cycle control [37]. Acronyms14-3-3
family proteins interact with many signaling molecules,
such as MAPK kinase kinase, Raf-1, Wee1, Cdc25, cyclin
B1, protein kinase C, IGF-I receptor, insulin receptor sub-
strate 1, Bad, and Bcl [38-42], and regulate several signal
transduction pathways [43-45]. Also, 14-3-3 proteins help
two molecules to interact or to interrupt the association
between two molecules by functioning as molecular scaf-
folds [46].
Binding of a protein to a 14-3-3 protein may result in sta-
bilization of the active or inactive phosphorylated form of
the protein, to a conformational alteration leading to acti-
vation or inhibition, to a different subcellular localization
or to the interaction with other proteins. Currently
genome- and proteome-wide studies are contributing to a
wider knowledge of this important family of proteins
[47].
The molecular consequences of 14-3-3 binding are diverse
and only partly understood. Disturbance of the interac-
tions with 14-3-3 proteins may lead to disease like cancer.
In this study, gremlin 1 binds YWHAH protein in vitro
and in vivo. We suspect that this binding may disturb the
interactions with 14-3-3 proteins and lead to disease like
cancer.
Conclusion
Gremlin 1 was overexpressed in various human tumors
and plays a oncogenic role especially in carcinomas of the
cervix, lung, ovary, kidney, breast, colon, pancreas and
sarcoma. Although further investigation with largerBMC Cancer 2006, 6:74 http://www.biomedcentral.com/1471-2407/6/74
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number of samples will be needed, these results indicate
that increased expression of the PIG-2 may be associated
with human tumorigenesis. Our study suggests that over-
expressed gremlin 1 functions by interaction with
YWHAH in human tumorigenesis. While further studies
are needed to characterize cellular functions and regula-
tory mechanisms, gremlin 1 is a candidate oncoprotein in
the development of many types of human cancers, and
gremlin 1 and its binding protein YWHAH could be good
targets for developing diagnostic and therapeutic strate-
gies against human cancers.
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